Atossa Therapeutics (ATOS) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Seres Therapeutics is the larger company by market cap ($26.4 million vs $24.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | MCRB |
|---|---|---|
| Share price | $2.42 | $2.63 |
| Market cap | $24.15M | $26.42M |
| 1-day change | -1.63% | -3.31% |
| YTD return | -72.66% | — |
| 1-year return | -85.47% | — |
| 5-year return | -94.36% | — |
| EPS (TTM) | $-4.45 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.00 | $29.98 |
| 52-week low | $1.70 | $2.42 |
| Distance from 52-week high | -86.56% | -91.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +685.12% | +546.39% |
| Average volume | 63.48K | 73.43K |
| Shares outstanding | 9.98M | 10.04M |
| Employees | 16 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
ATOS vs MCRB FAQ
Which is bigger, Atossa Therapeutics or Seres Therapeutics?
Seres Therapeutics (MCRB) is larger, with a market capitalization of $26.42M compared with $24.15M for Atossa Therapeutics (ATOS).
Are Atossa Therapeutics and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.